Miravant Medical Technologies Inc. (MRVT)

USD 0.0

(0.0%)

Market Cap (In USD)

379.00

Revenue (In USD)

-

Net Income (In USD)

-15.89 Million

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-6-1.0E-5
PE
-
EPS
-
Beta Value
1.502
ISIN
US6046901079
CUSIP
604690107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. David E. Mai
Employee Count
-
Website
-
Ipo Date
1995-04-11
Details
Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.